Parameter
| Biomarker | CA125 | Full name | Carbohydrate antigen 125 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ~200-500 kDa | Core Functional Dimensions | Congestion monitoring, treatment guidance | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Ovarian epithelium, pleural/peritoneal mesothelial cells, myocardium (congestion-induced) | Test Sample / Technology Platform | Plasma (immunoassay, chemiluminescence) | ||
| Pathobiological Mechanisms | Skin cells between interstitial pressure/inflammatory stimulate secretion, direct reflect vascular congestion (e.g., pleural effusion, peripheral edema) | ||||
| Clinical Availability Status | Early clinical research validation / : - CHANCE-HF experiments confirm its guiding value of diuretic therapy; -Prognostic value is superior to NT-proBNP in HF patients with severe tricuspid regurgitation (TR) | ||||
| Notes and Dynamics | Acute HF CA125 > 35 u/ml tip residual hyperemia, did not drop to normal discharge (< 35 u/ml) is 6 months and 2.1 times increased risk of hospitalization; In chronic HF, CA125 was highly correlated with right ventricular dysfunction (e.g., TAPSE<18mm) (r=0.53); With the NT-proBNP can promote HFpEF congestion detection accuracy (AUC from 0.82 to 0.89) | ||||